DarDoc Research

GLP-1 Trial & Approval Tracker

GLP-1 clinical studies

Published trials by medicine, population and endpoint, with results and original sources.

Clinical trial results at a glance

All weight charts
Phase 3b · 72 weeks

STEP UP

Wegovy injection
Mean body weight change
Semaglutide 7.2 mg
−18.7%
Semaglutide 2.4 mg
−15.6%
Placebo
−3.9%

Without diabetes · n=1,407

Phase 3b · 72 weeks

SURMOUNT-5

MounjaroWegovy injection
Mean body weight change
Tirzepatide 10 or 15 mg
−20.2%
Semaglutide 1.7 or 2.4 mg
−13.7%

Without type 2 diabetes · n=751

Phase 3b · 64 weeks

OASIS 4

Wegovy tablets
Mean body weight change
Oral semaglutide 25 mg
−13.6%
Placebo
−2.2%

Without diabetes · n=307

Study register

1 of 19 studies
StudyMedicinePopulation & follow-upPublished resultsSource
OASIS 4Phase 3b · 2025 · 307 participants
Wegovy tabletsWithout diabetes · 64 weeks
Wegovy tabletsWithout diabetes64 weeksMean body weight change at 64 weeks
Oral semaglutide 25 mg
−13.6%
Placebo
−2.2%
Paper

Open a study to see doses, comparators and the exact endpoint.